
Kidney Disease Treatment sNDA Submitted to FDA for Approval
Travere Therapeutics, Inc. announced the company has submitted a supplemental New Drug Application (sNDA) to the FDA seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). …